Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Reports Positive Data from Phase III Tyvyt Trial in NSCLC

publication date: Apr 13, 2021

Innovent Biologics of Suzhou reported positive data from a Phase III trial of its anti-PD-1 drug, Tyvyt®, as a second line therapy for patients with non-small cell lung cancer. Patients who received Tyvyt® experienced a statistically significant improvement in overall survival compared to those who received docetaxel. Currently, Innovent has three Tyvyt® NDAs under review in China. In addition, the company is conducting more than 20 clinical trials of Tyvyt® in a variety of cancer indications. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital